Liu, S. The development of our organ of other kinds-the gut microbiota. Front. Microbiol. 7, 2107 (2016).
Google ScholarÂ
Szajewska, H. Gut microbiota: no longer the forgotten organ. Ann. Nutr. Metab. 77, 1–2 (2021).
Baquero, F. & Nombela, C. The microbiome as a human organ. Clin. Microbiol. Infect. 18, 2–4 (2012).
Google ScholarÂ
Borody, T. J. & Khoruts, A. Fecal microbiota transplantation and emerging applications. Nat. Rev. Gastroenterol. Hepatol. 9, 88–96 (2011).
Google ScholarÂ
Vindigni, S. M. & Surawicz, C. M. Fecal microbiota transplantation. Gastroenterol. Clin. North Am. 46, 171–185 (2017).
Google ScholarÂ
Gupta, S., Allen-Vercoe, E. & Petrof, E. O. Fecal microbiota transplantation: in perspective. Ther. Adv. Gastroenterol. 9, 229–239 (2016).
Google ScholarÂ
DePeters, E. J. & George, L. W. Rumen transfaunation. Immunol. Lett. 162, 69–76 (2014).
Google ScholarÂ
Khoruts, A., Staley, C. & Sadowsky, M. J. Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology. Nat. Rev. Gastroenterol. Hepatol. 18, 67–80 (2021).
Google ScholarÂ
Frisbee, A. L. & Petri, W. A. Considering the immune system during fecal microbiota transplantation for Clostridioides difficile infection. Trends Mol. Med. 26, 496–507 (2020).
Google ScholarÂ
Lee, C. et al. Safety of fecal microbiota, live-jslm (REBYOTATM) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials. Ther. Adv. Gastroenterol. 16, 17562848231174277 (2023).
Google ScholarÂ
Wang, Y., Hunt, A., Danziger, L. & Drwiega, E. N. A comparison of currently available and investigational fecal microbiota transplant products for recurrent Clostridioides difficile infection. Antibiotics 13, 436 (2024).
Google ScholarÂ
Luu, L. D. W. et al. Profiling the colonic mucosal response to fecal microbiota transplantation identifies a role for GBP5 in colitis in humans and mice. Nat. Commun. 15, 2645 (2024).
Google ScholarÂ
Costello, S. P. et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA 321, 156–164 (2019).
Google ScholarÂ
Moayyedi, P. et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149, 102–109.e6 (2015).
Google ScholarÂ
Sokol, H. et al. Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study. Microbiome 8, 12 (2020).
Google ScholarÂ
Kao, D. et al. Preliminary results from a multicenter, randomized trial using fecal microbiota transplantation to induce remission in patients with mild-to-moderate Crohn’s disease. Am. J. Gastroenterol. 120, 1334–1344 (2024).
Google ScholarÂ
Bajaj, J. S. et al. Microbiota transplant for hepatic encephalopathy in cirrhosis: the THEMATIC trial. J. Hepatol. 83, 81–91 (2025).
Google ScholarÂ
Zhang, F. et al. Longitudinal dynamics of gut bacteriome, mycobiome and virome after fecal microbiota transplantation in graft-versus-host disease. Nat. Commun. 12, 65 (2021).
Google ScholarÂ
Reddi, S. et al. Fecal microbiota transplantation to prevent acute graft-versus-host disease: pre-planned interim analysis of donor effect. Nat. Commun. 16, 1034 (2025).
Google ScholarÂ
Groenewegen, B. et al. Consecutive fecal microbiota transplantation for metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial. Gut Microbes 17, 2541035 (2025).
Google ScholarÂ
Mocanu, V. et al. Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial. Nat. Med. 27, 1272–1279 (2021).
Google ScholarÂ
Zhou, X., Chen, R., Cai, Y. & Chen, Q. Fecal microbiota transplantation: a prospective treatment for type 2 diabetes mellitus. Diab. Metab. Syndr. Obes. 17, 647–659 (2024).
Google ScholarÂ
Böhm, D. et al. The role of the gut microbiota in chemotherapy response, efficacy and toxicity: a systematic review. NPJ Precis. Oncol. 9, 265 (2025).
Google ScholarÂ
Björk, J. R. et al. Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma. Nat. Med. 30, 785–796 (2024).
Google ScholarÂ
Gunjur, A. et al. A gut microbial signature for combination immune checkpoint blockade across cancer types. Nat. Med. 30, 797–809 (2024).
Google ScholarÂ
Routy, B. et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat. Med. 29, 2121–2132 (2023).
Google ScholarÂ
Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602–609 (2021).
Google ScholarÂ
Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595–602 (2021).
Google ScholarÂ
McCulloch, J. A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat. Med. 28, 545–556 (2022).
Google ScholarÂ
Fernandes, R. et al. Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial. Nat. Med. https://doi.org/10.1038/s41591-025-04183-8 (2026).
Duttagupta, S. et al. Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial. Nat. Med. https://doi.org/10.1038/s41591-025-04186-5 (2026).
Shen, X. et al. Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: a systematic review and meta-analysis. Front. Oncol. 14, 1391724 (2024).
Google ScholarÂ
Frey, C. & Etminan, M. Adverse events of PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitors: an analysis of the FDA adverse events database. Antibodies 13, 59 (2024).
Google ScholarÂ
Shatila, M. et al. Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events. J. Immunother. Cancer 12, e009742 (2024).
Google ScholarÂ
Dearden, H. et al. Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. Eur. J. Cancer 153, 168–178 (2021).
Google ScholarÂ
Pacholczak-Madej, R. et al. Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in Poland. BMC Cancer. 24, 1411 (2024).
Google ScholarÂ
Zhou, S., Khanal, S. & Zhang, H. Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients. Ther. Clin. Risk. Manag 15, 211–221 (2019).
Google ScholarÂ
Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749–1755 (2016).
Google ScholarÂ
Schneider, B. J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. J. Clin. Oncol. 39, 4073–4126 (2021).
Google ScholarÂ
Muir, C. A. et al. Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J. Clin. Endocrinol. Metab. 106, e3704–e3713 (2021).
Google ScholarÂ
Luoma, A. M. et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell 182, 655–671.e22 (2020).
Google ScholarÂ
Kim, Y. et al. Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor. Cell Host Microbe 32, 1380–1393.e9 (2024).
Google ScholarÂ
Halsey, T. M. et al. Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis. Sci. Transl. Med. 15, eabq4006 (2023).
Google ScholarÂ
Elkrief, A. et al. Immune-related colitis is associated with fecal microbial dysbiosis and can be mitigated by fecal microbiota transplantation. Cancer Immunol. Res. 12, 308–321 (2024).
Google ScholarÂ
Porcari, S. et al. Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial. Nat. Med. https://doi.org/10.1038/s41591-025-04189-2 (2026).
Google ScholarÂ
Walter, J., Maldonado-Gómez, M. X. & MartÃnez, I. To engraft or not to engraft: an ecological framework for gut microbiome modulation with live microbes. Curr. Opin. Biotechnol. 49, 129–139 (2018).
Google ScholarÂ
He, R. et al. The interplay of gut microbiota between donors and recipients determines the efficacy of fecal microbiota transplantation. Gut Microbes 14, 2100197 (2022).
Google ScholarÂ
Schmidt, T. S. B. et al. Drivers and determinants of strain dynamics following fecal microbiota transplantation. Nat. Med. 28, 1902–1912 (2022).
Google ScholarÂ
Ianiro, G. et al. Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases. Nat. Med. 28, 1913–1923 (2022).
Google ScholarÂ
Danne, C., Rolhion, N. & Sokol, H. Recipient factors in faecal microbiota transplantation: one stool does not fit all. Nat. Rev. Gastroenterol. Hepatol. 18, 503–513 (2021).
Google ScholarÂ
Iljazovic, A. et al. Perturbation of the gut microbiome by Prevotella spp. enhances host susceptibility to mucosal inflammation. Mucosal Immunol. 14, 113–124 (2021).
Google ScholarÂ
Zheng, J. et al. Alcaligenes faecalis promotes colitis to colorectal cancer transition through IgA+ B cell suppression and vinculin acetylation. Gut Microbes 17, 2473511 (2025).
Google ScholarÂ
Yu, A. I. et al. Gut microbiota modulate CD8 T cell responses to influence colitis-associated tumorigenesis. Cell Rep. 31, 107471 (2020).
Google ScholarÂ
Hashimoto, M. et al. CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu. Rev. Med. 69, 301–318 (2018).
Google ScholarÂ
Griffin, M. E. et al. Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy. Science 373, 1040–1046 (2021).
Google ScholarÂ
Shang, J. et al. Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis. J. Exp. Med. 222, e20232079 (2025).
Google ScholarÂ
Huang, D. et al. Association between airway microbiota and systemic inflammation markers in non-small cell lung cancer patients. Sci. Rep. 15, 3539 (2025).
Google ScholarÂ
Smillie, C. S. et al. Strain tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation. Cell Host Microbe 23, 229–240.e5 (2018).
Google ScholarÂ
Gan, Y., Li, Z., Ruan, M. & Yang, Y. A pilot metabolomics study on clear cell renal cell carcinoma. BMC Urol. 25, 82 (2025).
Google ScholarÂ
Luo, J. et al. Cortisol synergizing with endoplasmic reticulum stress induces regulatory T-cell dysfunction. Immunology 170, 334–343 (2023).
Google ScholarÂ
Zefferino, R., Di Gioia, S. & Conese, M. Molecular links between endocrine, nervous and immune system during chronic stress. Brain Behav. 11, e01960 (2021).
Google ScholarÂ
Solvay, M. et al. Tryptophan depletion sensitizes the AHR pathway by increasing AHR expression and GCN2/LAT1-mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytes. J. Immunother. Cancer. 11, e006728 (2023).
Google ScholarÂ
Ala, M. Tryptophan metabolites modulate inflammatory bowel disease and colorectal cancer by affecting immune system. Int. Rev. Immunol. 41, 326–345 (2022).
Google ScholarÂ
Yan, J. et al. Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer. Mol. Cancer. 23, 241 (2024).
Google ScholarÂ
Seo, S.-K. & Kwon, B. Immune regulation through tryptophan metabolism. Exp. Mol. Med. 55, 1371–1379 (2023).
Google ScholarÂ
Tian, L. et al. Deciphering functional redundancy in the human microbiome. Nat. Commun. 11, 6217 (2020).
Google ScholarÂ
Louca, S. et al. Function and functional redundancy in microbial systems. Nat. Ecol. Evol. 2, 936–943 (2018).
Google ScholarÂ
Podlesny, D. et al. Identification of clinical and ecological determinants of strain engraftment after fecal microbiota transplantation using metagenomics. Cell Rep. Med. 3, 100711 (2022).
Google ScholarÂ
Chen, Q. Y. et al. Effect of intestinal preparation on the efficacy and safety of fecal microbiota transplantation treatment. Zhonghua Wei Chang Wai Ke Za Zhi. 23, 48–55 (2020).
Google ScholarÂ
Glitza, I. C. et al. Randomized placebo-controlled, biomarker-stratified phase Ib microbiome modulation in melanoma: impact of antibiotic preconditioning on microbiome and immunity. Cancer Discov. 14, 1161–1175 (2024).
Google ScholarÂ
Abu-Sbeih, H. et al. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. J. Immunother. Cancer. 7, 242 (2019).
Google ScholarÂ
Elkrief, A. et al. Gut microbiota in immuno-oncology: a practical guide for medical oncologists with a focus on antibiotics stewardship. Am. Soc. Clin. Oncol. Educ. Book 45, e472902 (2025).
Google ScholarÂ
Quaranta, G. et al. Fecal microbiota transplantation and other gut microbiota manipulation strategies. Microorganisms 10, 2424 (2022).
Google ScholarÂ
Vemuri, R. et al. The microgenderome revealed: sex differences in bidirectional interactions between the microbiota, hormones, immunity and disease susceptibility. Semin. Immunopathol. 41, 265–275 (2019).
Google ScholarÂ
Sheng, L., Jena, P. K., Hu, Y. & Wan, Y.-J. Y. Age-specific microbiota in altering host inflammatory and metabolic signaling as well as metabolome based on the sex. Hepatobiliary Surg. Nutr. 10, 31–48 (2021).
Google ScholarÂ
El-Salhy, M., Casen, C., Valeur, J., Hausken, T. & Hatlebakk, J. G. Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome. World J. Gastroenterol. 27, 2219–2237 (2021).
Google ScholarÂ
Anand, R. et al. Effect of aging on the composition of fecal microbiota in donors for FMT and its impact on clinical outcomes. Dig. Dis. Sci. 62, 1002–1008 (2017).
Google ScholarÂ
Kim, Y.-I., Choi, W., Seo, M., Ka, S. & Park, J. Effect of exercise on the human gut microbiota in individuals with overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Phys. Act. Nutr. 29, 49–61 (2025).
Google ScholarÂ
Men, J. et al. Fecal bacteria transplantation replicates aerobic exercise to reshape the gut microbiota in mice to inhibit high-fat diet-induced atherosclerosis. PLoS ONE 20, e0314698 (2025).
Google ScholarÂ
Zhao, L. et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science 359, 1151–1156 (2018).
Google ScholarÂ
Fox, E. & Lyte, M. Variation in spatial organization of the gut microbiota along the longitudinal and transverse axes of the intestines. Arch. Microbiol. 204, 424 (2022).
Google ScholarÂ
Li, N. et al. Spatial heterogeneity of bacterial colonization across different gut segments following inter-species microbiota transplantation. Microbiome 8, 161 (2020).
Google ScholarÂ
Procházková, N. et al. Advancing human gut microbiota research by considering gut transit time. Gut. 72, 180–191 (2023).
Google ScholarÂ
Kim, M. S. & Bisanz, J. E. Design and application of synthetic human gut microbial communities. Gut Microbes 17, 2575923 (2025).
Google ScholarÂ
Rios-Covian, D., Gueimonde, M., Duncan, S. H., Flint, H. J. & de los Reyes-Gavilan, C. G. Enhanced butyrate formation by cross-feeding between Faecalibacterium prausnitzii and Bifidobacterium adolescentis. FEMS Microbiol Lett. 362, fnv176 (2015).
Google ScholarÂ
Zhao, S., Lau, R., Zhong, Y. & Chen, M.-H. Lactate cross-feeding between Bifidobacterium species and Megasphaera indica contributes to butyrate formation in the human colonic environment. Appl. Environ. Microbiol. 90, e0101923 (2024).
Google ScholarÂ
Livanos, A. E. et al. Rapid gastrointestinal loss of clostridial clusters IV and XIVa in the ICU associates with an expansion of gut pathogens. PLoS ONE 13, e0200322 (2018).
Google ScholarÂ
Khademian, M. & Imlay, J. A. Do reactive oxygen species or does oxygen itself confer obligate anaerobiosis? The case of Bacteroides thetaiotaomicron. Mol. Microbiol 114, 333–347 (2020).
Google ScholarÂ
De Filippis, F. et al. Distinct Genetic and functional traits of human intestinal prevotella copri strains are associated with different habitual diets. Cell Host Microbe 25, 444–453.e3 (2019).
Google ScholarÂ
Lam, S. et al. Roles of the gut virome and mycobiome in faecal microbiota transplantation. Lancet Gastroenterol. Hepatol. 7, 472–484 (2022).
Google ScholarÂ
Seelbinder, B. et al. Candida expansion in the gut of lung cancer patients associates with an ecological signature that supports growth under dysbiotic conditions. Nat. Commun. 14, 2673 (2023).
Google ScholarÂ
Zhang, L. et al. Association of survival and immune-related adverse events with anti-PD-1/PD-L1 and anti-CTLA-4 inhibitors, alone or their combination for the treatment of cancer: a systematic review and meta-analysis of 13 clinical trials. Front. Oncol. 11, 575457 (2021).
Google ScholarÂ
Wolchok, J. D. et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J. Clin. Oncol. 40, 127–137 (2022).
Google ScholarÂ
Li, Z. et al. Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real-world adverse events from the FDA adverse event reporting system for tremelimumab, durvalumab, ipilimumab, and nivolumab. Front. Immunol. 16, 1631273 (2025).
Google ScholarÂ
Schubert, D. et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat. Med. 20, 1410–1416 (2014).
Google ScholarÂ
Lo, J. W. et al. CTLA-4 expressing innate lymphoid cells modulate mucosal homeostasis in a microbiota dependent manner. Nat. Commun. 15, 9520 (2024).
Google ScholarÂ
Wei, S. C. et al. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc. Natl. Acad. Sci. USA 116, 22699–22709 (2019).
Google ScholarÂ
Liu, B. et al. Starvation responses impact interaction dynamics of human gut bacteria Bacteroides thetaiotaomicron and Roseburia intestinalis. ISME J. 17, 1940–1952 (2023).
Google ScholarÂ
Culp, E. J. & Goodman, A. L. Cross-feeding in the gut microbiome: ecology and mechanisms. Cell Host Microbe 31, 485–499 (2023).
Google ScholarÂ
Simpson, R. C. et al. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome. Nat. Med. 28, 2344–2352 (2022).
Google ScholarÂ
Chau, J. et al. Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer. BMC Cancer. 21, 808 (2021).
Google ScholarÂ
Jin, Y. et al. The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC. J. Thorac. Oncol. 14, 1378–1389 (2019).
Google ScholarÂ
Wilson, B. C. et al. Strain engraftment competition and functional augmentation in a multi-donor fecal microbiota transplantation trial for obesity. Microbiome 9, 107 (2021).
Google ScholarÂ
Behling, A. H. et al. Cohort-specific determinants of donor strain engraftment following multi-donor faecal microbiota transplantation in two randomised clinical trials. Gut. Microbes 17, 2597628 (2025).
Google ScholarÂ
Li, S. et al. Short-chain fatty acids and cancer. Trends Cancer 11, 154–168 (2025).
Google ScholarÂ
Li, R. et al. Prevotella copri leads to colonic barrier dysfunction via the succinate receptor 1-FoxM1-IL-6 axis. Biochim. Biophys. Acta Mol. Cell Res. 1873, 120099 (2025).
Google ScholarÂ
Sepúlveda-Pontigo, A. et al. Segatella copri outer-membrane vesicles are internalized by human macrophages and promote a pro-inflammatory profile. Int. J. Mol. Sci. 26, 3630 (2025).
Google ScholarÂ
Hadi, D. K. et al. Improved survival in advanced melanoma patients treated with fecal microbiota transplantation using healthy donor stool in combination with anti-PD1: final results of the MIMic phase 1 trial. J. Immunother. Cancer. 13, e012659 (2025).
Google ScholarÂ
Gao, Y. et al. Faecalibacterium prausnitzii abrogates intestinal toxicity and promotes tumor immunity to increase the efficacy of dual CTLA4 and PD-1 checkpoint blockade. Cancer. Res. 83, 3710–3725 (2023).
Google ScholarÂ
Ma, Z., Wang, Z., Cao, J., Dong, Y. & Chen, Y. Regulatory roles of intestinal CD4+ T cells in inflammation and their modulation by the intestinal microbiota. Gut Microbes 17, 2560019 (2025).
Google ScholarÂ
Cao, T. et al. The epigenetic modification during the induction of Foxp3 with sodium butyrate. Immunopharmacol. Immunotoxicol. 40, 309–318 (2018).
Google ScholarÂ
Guo, X. et al. Microbial anti-inflammatory molecule (MAM) secreted by Faecalibacterium prausnitzii ameliorates colitis through autophagy and gut microbiota modulation. J. Transl. Med. https://doi.org/10.1186/s12967-025-07493-0 (2025).
Yao, L. et al. The secreted metabolite isopentenyladenine from Faecalibacterium prausnitzii is anti-inflammatory with barrier-protective properties. ACS Infect. Dis. 12, 224–236 (2026).
Google ScholarÂ
Qin, W. et al. Faecalibacterium prausnitzii enhances intestinal IgA response by host-microbe derived inecalcitol in colitis. BMC Med. 23, 425 (2025).
Google ScholarÂ
Li, Y. et al. Bifidobacterium breve protects the intestinal epithelium and mitigates inflammation in colitis via regulating the gut microbiota-cholic acid pathway. J. Agric Food Chem. 72, 3572–3583 (2024).
Google ScholarÂ
Schell, M. A. et al. The genome sequence of Bifidobacterium longum reflects its adaptation to the human gastrointestinal tract. Proc. Natl. Acad. Sci. USA 99, 14422–14427 (2002).
Google ScholarÂ
Bakshani, C. R. et al. Carbohydrate-active enzymes from Akkermansia muciniphila break down mucin O-glycans to completion. Nat. Microbiol. 10, 585–598 (2025).
Google ScholarÂ
Liu, C. S. et al. Towards optimising and standardising donor screening for faecal microbiota transplantion. Gut https://doi.org/10.1136/gutjnl-2025-336532 (2025).
Li, Z. et al. Shotgun metagenomics reveals abnormal short-chain fatty acid-producing bacteria and glucose and lipid metabolism of the gut microbiota in patients with schizophrenia. Schizophr. Res. 255, 59–66 (2023).
Google ScholarÂ
Drew, G., Kraft, C. S. & Mehta, N. Fecal microbiota therapy: clinical laboratory testing and metabolomic approaches for donor screening, product assessment, and patient monitoring. Clin. Chem. https://doi.org/10.1093/clinchem/hvaf156 (2025).
Bylsma, S., Yun, K., Patel, S. & Dennis, M. J. Immune checkpoint inhibitor rechallenge after prior immune toxicity. Curr. Treat. Options Oncol. 23, 1153–1168 (2022).
Google ScholarÂ
Hsu, M. L. et al. Clinical features, survival, and burden of toxicities in survivors more than one year after lung cancer immunotherapy. Oncologist 27, 971–981 (2022).
Google ScholarÂ
Tong, J., Kartolo, A., Yeung, C., Hopman, W. & Baetz, T. Long-term toxicities of immune checkpoint inhibitor (ICI) in melanoma patients. Curr. Oncol. 29, 7953–7963 (2022).
Google ScholarÂ
